Slide 1: Filing cover letter: Presentation and Video Recording of Q3 FY23 Earnings Call
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com February 15, 2023 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corpo
Slide 2: Q3 FY23 Earnings Call
Q3 FY23 Earnings Call February 15, 2023 B I O C O N L I M I T E D 1
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 4: Opening Remarks
Opening Remarks B I O C O N L I M I T E D 33
Slide 5: Opening Remarks: Q3 FY23 Earnings Call
Opening Remarks: Q3 FY23 Earnings Call National budget spotlight on research and innovation Viatris transaction completed; business integration in a phased manner Debt reduction efforts Recent FDA actions impacting Indian pharma industry B I O C O N L I M I T E D 4
Slide 6: Viatris acquisition completed
Viatris acquisition completed B U S I N E S S I N T E G R AT I O N E Q U I T Y I N F U S I O N I N B B L Incremental revenues & profits post deal closure reflected in earnings SILS $150m Bespoke country specific strategy and business model that optimizes for revenues and profitability Biocon Ltd $65
Slide 7: Opening Remarks: Recent Regulatory Inspections
Opening Remarks: Q3 FY23 Earnings Call R E C E N T R E G U L AT O RY I N S P E C T I O N S National budget spotlight on research and innovation Viatris transaction completed; business integration in a phased manner Debt reduction efforts Recent FDA actions impacting Indian pharma industry B I O C O
Slide 8: Leadership Update
Leadership Update B I O C O N L I M I T E D 77
Slide 9: Leadership Update
Leadership Update Dr. Arun Chandavarkar Shreehas Tambe Non-Executive, non-Independent Director Appointed CEO and Managing Director of on the Board of Biocon Biologics Biocon Biologics in December 2022 B I O C O N L I M I T E D 8
Slide 10: Q3 FY23 Financial Highlights
Q3 FY23 Financial Highlights B I O C O N L I M I T E D 99
Slide 11: Financial Highlights: Q3 FY23
Financial Highlights: Q3 FY23 Consolidated (in INR Cr.) Q3 FY23 Q3 FY22 YoY % Total Revenue 3,020 2,223 36 Biosimilars +54% | Research +23% | Generics +18% Core EBITDA1 1,069 715 49 % Margin 36% 33% Net R&D spend at ₹337Cr, up ₹199 Cr vs Q3 FY22 EBITDA 723 537 35 Forex Loss of ₹44Cr vs gain of ₹19 C
Slide 12: Exceptional Items: Q3 FY23
Exceptional Items: Q3 FY23 Consolidated (in INR Cr.) Q3 FY23 Q3 FY22 YoY % Net Profit 140 187 (25) (before exceptional charge) Exceptional items during Q3 FY23: Exceptional Items (182) - Primarily pertain to deal related expenses of the (net of tax and minority interest) Viatris transaction. . Net P
Slide 13: Q3 FY23 Generics
Q3 FY23 Generics B I O C O N L I M I T E D 12 12
Slide 14: Generics: Q3 FY23 Update
Generics: Q3 FY23 Update K E Y H I G H L I G H T S Revenue growth led by increased demand for Immunosuppressant APIs as well as Generic Formulations In INR Cr Q3 FY23 Q3 FY22 YoY % Margins, compared to the previous year were muted due to continued Segment Revenue 718 607 18 pricing pressure in the U
Slide 15: Q3 FY23 Biosimilars
Q3 FY23 Biosimilars B I O C O N L I M I T E D 14 14
Slide 16: Biosimilars: Q3 FY23 Update
Biosimilars: Q3 FY23 Update K E Y H I G H L I G H T S Revenue growth of 54% driven by Viatris deal closure and steady growth in BBL-led business In INR Cr Q3 FY23 Q3 FY22 YoY % R&D investments increased to ₹280 Crores; completed recruitment Segment Revenue 1,507 981 54 for bDenosumab and bUstekinuma
Slide 17: Q3 FY23 Novels
Q3 FY23 Novels B I O C O N L I M I T E D 16 16
Slide 18: Novels: Q3 FY23 Update
Novels : Q3 FY23 Update K E Y H I G H L I G H T S Enrolment continues to ramp up in the pivotal Phase III clinical study of Itolizumab in patients with aGVHD* (EQUATOR study) Patient enrolment also continues for the pivotal Phase 1b clinical study of Itolizumab for Lupus Nephritis (equalise study) T
Slide 19: Q3 FY23 Research Services
Q3 FY23 Research Services B I O C O N L I M I T E D 18 18
Slide 20: Research Services: Q3 FY23 Update
Research Services: Q3 FY23 Update K E Y H I G H L I G H T S Delivered positive performances in all divisions. Sustained growth in Research divisions - Discovery Services and the Dedicated Centers In INR Cr Q3 FY23 Q3 FY22 YoY % Development Services growth primarily driven by repeat orders from Segme
Slide 21: Concluding Remarks
Concluding Remarks B I O C O N L I M I T E D 20 20
Slide 22: Q&A
Q&A B I O C O N L I M I T E D 21 21